IDO1 and head and neck squamous cell carcinoma: Atezolizumab has also been investigated in the treatment of HNSCC, with the combination of atezolizumab and GDC-0919 (IDO1 inhibitor) showing a controlled safety profile in a phase I clinical trial (NCT02471846) in advanced HNSCC (Jung et al., 2019).